Janssen Pharmaceutica N.V., Funds New Global Mental Health Scholarships as Part of Its Healthy Minds Program
3/5/2013 1:09:43 PM
More...
|
Galapagos NV (GLPG.BR) Delivers Candidate Drug in Its Alliance With Janssen Pharmaceutica N.V. and Receives $5.3 Million Milestone Payment
1/16/2013 8:53:53 AM
More...
|
New Janssen Pharmaceutica N.V. Data Demonstrate STELARA® (ustekinumab) is Effective, Well-Tolerated and Improved Quality of Life in Patients With Moderate to Severe Plaque Psoriasis
9/28/2012 10:07:12 AM
More...
|
ImmuNext Enters Into a Strategic Partnership With Janssen Pharmaceutica N.V. to Develop Novel Immunotherapies for the Treatment of Cancer
9/5/2012 9:59:40 AM
More...
|
Janssen Pharmaceutica N.V. Enters Alliance With CureBeta for Up to $308 Million
7/10/2012 7:33:04 AM
More...
|
Janssen Pharmaceutica N.V. Companies of Johnson & Johnson (JNJ) Sponsors 2012 Biotechnology Industry Organization (BIO) International Convention, Jun 18 - 21, 2012, in Boston MA, US
6/18/2012 10:31:46 AM
More...
|
Janssen Pharmaceutica N.V. Creates New Division to Launch TMC435 and Help Conquer Hepatitis C in EMEA
4/19/2012 9:51:29 AM
More...
|
Janssen Pharmaceutica N.V. Release: INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV
4/18/2012 10:51:45 AM
More...
|
Janssen Pharmaceutica N.V. Release: INCIVO ® (Telaprevir) in Combination With Peginterferon Alfa and Ribavirin is Cost-effective for Both Treatment-naïve and Experienced Patients With Chronic Genotype-1 Hepatitis C Virus
4/5/2012 8:49:54 AM
More...
|
Forest Laboratories, Inc. (FRX) Buys Blood Pressure Drug Bystolic From Johnson & Johnson (JNJ)'s Janssen Pharmaceutica N.V. for $357 Million
4/2/2012 7:26:23 AM
More...
|
|